VNRX (VolitionRx Limited)
Insider Trading Activity
Every open-market purchase and sale reported by VNRX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-19 | Nicholas Plummer | GC - Volition Diagnostics | F | — | — |
| 2026-03-19 | Rodney Gerard Rootsaert | Secretary | F | — | — |
| 2026-03-19 | Gael Forterre | Chief Commercial Officer | F | — | — |
| 2026-03-19 | Jacob Vincent Micallef | Chief Scientific Officer | F | — | — |
| 2026-03-03 | Nicholas Plummer | GC - Volition Diagnostics | F | — | — |
| 2026-03-03 | Gael Forterre | Chief Commercial Officer | F | — | — |
| 2026-03-03 | Rodney Gerard Rootsaert | Secretary | F | — | — |
| 2026-02-27 | Terig Hughes | Chief Financial Officer | A | — | — |
| 2026-02-27 | Gael Forterre | Chief Commercial Officer | A | — | — |
| 2026-02-27 | Cameron John Reynolds | President and CEO | A | — | — |
| 2026-02-27 | Nicholas Plummer | GC - Volition Diagnostics | A | — | — |
| 2026-02-27 | Ethel Rubin | Director | A | — | — |
| 2026-02-27 | Ann-Louise Batchelor | Group Chief Marketing Officer | A | — | — |
| 2026-02-27 | Jasmine Kway | CEO - Singapore Volition | A | — | — |
| 2026-02-27 | Rodney Gerard Rootsaert | Secretary | A | — | — |
| 2026-02-27 | Kim Nguyen | Director | A | — | — |
| 2026-02-27 | Jacob Vincent Micallef | Chief Scientific Officer | A | — | — |
| 2026-02-27 | Guy Archibald Innes | Director | A | — | — |
| 2026-02-03 | Nicholas Plummer | GC - Volition Diagnostics | F | — | — |
| 2026-02-03 | Gael Forterre | Chief Commercial Officer | F | — | — |
| 2026-02-03 | Rodney Gerard Rootsaert | Secretary | F | — | — |
| 2026-01-23 | Terig Hughes | Chief Financial Officer | A | — | — |
| 2026-01-23 | Mickie Henshall | Director | A | — | — |
| 2026-01-23 | Nicholas Plummer | GC - Volition Diagnostics | A | — | — |
| 2026-01-23 | Ann-Louise Batchelor | Group Chief Marketing Officer | A | — | — |
| 2026-01-23 | TIMOTHY I STILL | Director | A | — | — |
| 2026-01-23 | Phillip Barnes | Director | A | — | — |
| 2026-01-23 | Jacob Vincent Micallef | Chief Scientific Officer | A | — | — |
| 2026-01-23 | Cameron John Reynolds | President and CEO | A | — | — |
| 2026-01-23 | Alan Colman | Director | A | — | — |
| 2026-01-23 | Rodney Gerard Rootsaert | Secretary | A | — | — |
| 2026-01-23 | Jasmine Kway | CEO - Singapore Volition | A | — | — |
| 2026-01-23 | Salvatore Thomas Butera | CEO - Volition Veterinary | A | — | — |
| 2026-01-23 | Gael Forterre | Chief Commercial Officer | A | — | — |
| 2026-01-23 | Guy Archibald Innes | Director | A | — | — |
| 2026-01-23 | Kim Nguyen | Director | A | — | — |
| 2026-01-23 | Ethel Rubin | Director | A | — | — |
| 2025-11-17 | Cameron John Reynolds | President and CEO | Buy | — | — |
| 2025-11-04 | Andrew Retter | Chief Medical Officer | F | — | — |
| 2025-11-04 | Nicholas Plummer | GC - Volition Diagnostics | F | — | — |
| 2025-11-04 | Salvatore Thomas Butera | CEO - Volition Veterinary | F | — | — |
| 2025-11-04 | Rodney Gerard Rootsaert | Secretary | F | — | — |
| 2025-11-04 | Gael Forterre | Chief Commercial Officer | F | — | — |
| 2025-10-15 | TIMOTHY I STILL | Director | Buy | — | — |
| 2025-10-15 | Cameron John Reynolds | President and CEO | Buy | — | — |
| 2025-10-15 | Guy Archibald Innes | Director | Buy | — | — |
| 2025-10-07 | Nicholas Plummer | GC - Volition Diagnostics | F | — | — |
| 2025-10-07 | Rodney Gerard Rootsaert | Secretary | F | — | — |
| 2025-10-07 | Jacob Vincent Micallef | Chief Scientific Officer | F | — | — |
| 2025-10-07 | Gael Forterre | Chief Commercial Officer | F | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | President and CEO | 206,163 | — |
| — | Director | 132,648 | — |
| — | Executive Director | 104,810 | — |
| — | Director | 81,273 | — |
| — | Secretary | 64,086 | — |
| — | Chief Financial Officer | 34,248 | — |
| — | Chief Scientific Officer | 31,359 | — |
| — | Director | 21,822 | — |
| — | CEO - Singapore Volition | 21,451 | — |
| — | GC - Volition Diagnostics | 20,363 | — |
| — | Group Chief Marketing Officer | 17,674 | — |
| — | 10%+ Owner | 16,921 | — |
| — | Director | 16,819 | — |
| — | Chief Commercial Officer | 16,817 | — |
| — | 10%+ Owner | 14,921 | — |
| — | Director | 12,868 | — |
| — | Chief Operating Officer | 12,837 | — |
| — | Director | 12,647 | — |
| — | Chief Medical Officer | 7,328 | — |
| — | CEO - Volition Veterinary | 4,968 | — |
| — | Director | 3,368 | — |
| — | Director | 2,210 | — |
| — | Chief Medical Officer | 1,659 | — |
| — | Director | 1,397 | — |
| — | Director | 977 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the VNRX quote page; the site-wide leaderboard is on the insider transactions hub.